Replacing insulin with immunotherapy: Time for a paradigm change in Type 1 diabetes

Tatovic, Danijela ORCID: https://orcid.org/0000-0002-3879-2686 and Dayan, Colin M ORCID: https://orcid.org/0000-0002-6557-3462 2021. Replacing insulin with immunotherapy: Time for a paradigm change in Type 1 diabetes. Diabetic Medicine 38 , e14696. 10.1111/dme.14696

Full text not available from this repository.

Abstract

For almost a hundred years, the management of Type 1 diabetes has not advanced beyond insulin replacement. However, insulin does not provide satisfactory glycaemic control in the majority of individuals and there remains a major unmet need for novel treatments for Type 1 diabetes. Immunomodulation to preserve beta-cell function offers the prospect of making treatment with insulin easier and/or preventing the need for insulin, particularly when it comes to novel low-risk immunotherapies. Led by the concept that the best insulin-producing cell is a patient's own beta-cell, the Type 1 diabetes scientific community has a challenging task ahead—to fundamentally change the management of this devastating disease by using low-risk immunotherapy to preserve endogenous beta-cell function and make metabolic control substantially easier. In that way, insulin and/or beta-cell replacement (stem cell or transplantation) should in the future be considered rescue therapies reserved for delayed presentations.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Wiley
ISSN:	0742-3071
Date of First Compliant Deposit:	7 October 2021
Date of Acceptance:	22 September 2021
Last Modified:	10 Nov 2022 09:51
URI:	https://orca.cardiff.ac.uk/id/eprint/144728

Citation Data

Cited 2 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item